This inventor holds 3 USPTO granted patents and 3 EPO patents. Top assignee: Mitsubishi Tanabe Pharma Corporation. Active years: 2012-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012-2015
Title: Koichi Tanimoto: Innovator in Pharmaceutical Chemistry
Introduction
Koichi Tanimoto is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of therapeutic agents. With a total of 3 patents to his name, Tanimoto's work is recognized for its innovative approaches to drug development.
Latest Patents
Tanimoto's latest patents include a method for producing optically active naphthalene compounds. This invention provides an industrially advantageous method for creating compounds that are useful as therapeutic agents for conditions such as dermatitis. The process involves several steps, including the reaction of specific compounds in the presence of a base and a catalyst, followed by asymmetrical hydrogenation and treatment with a reducing agent. Another significant patent involves pyrazolo[1,5-a]pyrimidine compounds, which act as CB1 receptor antagonists. These compounds are characterized by their unique formula, which includes optionally substituted aryl groups.
Career Highlights
Koichi Tanimoto is currently employed at Mitsubishi Tanabe Pharma Corporation, where he continues to advance his research in pharmaceutical innovations. His work has been instrumental in developing new therapeutic strategies that address various medical conditions.
Collaborations
Tanimoto collaborates with talented colleagues, including Mariko Oi and Yasunori Tsuboi. Their combined expertise contributes to the innovative research environment at Mitsubishi Tanabe Pharma Corporation.
Conclusion
Koichi Tanimoto's contributions to pharmaceutical chemistry highlight his role as a leading inventor in the field. His innovative patents and collaborative efforts continue to pave the way for advancements in therapeutic agents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
